Coated Tablet Plant Project Report: Industry Trends, Plant Setup, Machinery, Raw Materials, Investment Opportunities, Cost and Revenue

Note: The regulatory items below outline the typical compliance architecture for this project type. Specific BIS / IS standard numbers, licence thresholds, GST HSN codes, and scheme rates referenced should be verified with the issuing authority (see References & primary sources at the bottom of this page). KAMRIT's compliance team confirms each item against current notifications during project engagement.

The licence and approval architecture for pharmaceutical tablet manufacturing involves a multi-layered statutory framework administered by central and state regulatory authorities. Compliance with Schedule M of the Drugs and Cosmetics Rules, 1945, which prescribes WHO-GMP standards, is the foundational requirement for establishing manufacturing credibility and accessing domestic tender and export markets. The Central Drugs Standard Control Organisation (CDSCO) regulates new drug approvals and clinical trial permissions, while state Drugs Controllers issue manufacturing licences and conduct periodic inspections.

• CDSCO Manufacturing Licence: Form 25 (for operating a pharmacy) or Form 28 (for manufacturing licence for allopathic drugs) under the Drugs and Cosmetics Act, 1940, requires site registration, equipment validation, and quality control infrastructure demonstration before grant of licence.
• Schedule M Compliance (WHO-GMP): Mandatory adherence to infrastructure specifications including air-handling systems, water purification (purified water and water for injection systems), segregation of areas, and documentation protocols for batch manufacturing and testing records.
• State Pollution Control Board Consent: Consent to establish and operate under the Water Act, 1974, and Air Act, 1981, with specific effluent treatment plant specifications for pharmaceutical waste including solvent recovery systems and hazardous waste authorisation under the Hazardous and Other Wastes Rules, 2016.
• Drug Testing Laboratory Accreditation: Testing facilities must either establish in-house quality control laboratories meeting NABL accreditation parameters or engage NABL-accredited contract testing laboratories for release testing, with specific requirements for dissolution testing apparatus, HPLC, and UV-visible spectrophotometers.
• GST Registration and GST-OTC Compliance: Mandatory GST registration with composition scheme eligibility for small manufacturers (turnover below ₹1.5 crore), plus compliance with pharmaceutical-specific GST return filing schedules and e-invoice integration for B2B sales.
• Factory Licence under Factories Act, 1948: State-level factory licence requiring safety officer appointment, occupational health provisions, and annual renewal with compliance verification by the Directorate of Industrial Safety and Health.
• MSME Udyam Registration: Eligibility for priority sector lending benefits, state government incentive schemes, and access to CGTMSEguaranteed credit facilities for micro, small, and medium enterprise classifications applicable to facilities with investment below ₹50 crore in plant and machinery.
• Pharmacovigilance Programme of India (PvPI) Registration: Mandatory adverse event reporting infrastructure for domestic market supply, requiring designated drug safety officer and electronic reporting system connectivity to CDSCO PvPI cell.

KAMRIT Financial Services LLP manages the complete regulatory filing architecture for the Coated Tablet Plant from CDSCO licence applications through Schedule M compliance documentation, state pollution consents, and ongoing statutory renewals. Our team coordinates with state Drugs Controllers across target operating geographies and ensures NABL laboratory integration, pharmacovigilance system establishment, and GST compliance infrastructure are operational from day one of commercial production.

The coated tablet segment represents the largest sub-segment within oral solid dosage formulations, accounting for approximately 35-40% of total domestic pharmaceutical production by volume. Within the broader oral solid dosage category, coated tablets command a pricing premium of 15-25% over uncoated variants due to superior stability, controlled release capabilities, and patient compliance advantages. The sub-segment exhibits distinct growth gradients across therapeutic categories: cardiovascular and anti-diabetic coatings are growing at 18-22% annually driven by chronic disease prevalence, while anti-infective coated tablets are expanding at 12-14% reflecting renewed antibiotic manufacturing localization.

Gastrointestinal and nutraceutical coatings represent the fastest-growing niche at 25-28% CAGR, driven by lifestyle disease management and preventive healthcare adoption. The distinction between conventional film-coated tablets and advanced controlled-release formulations is commercially significant, with the latter commanding 3-5x per-unit realisation. The Ayushman Bharat ecosystem and expanding hospital networks in emerging cities are creating sustained demand for cost-effective generic coated tablets, while the chronic therapy segment (diabetes, hypertension, thyroid disorders) requires long-course treatments generating recurring volume.

The Kirana channel accounts for 55-60% of retail sales, while hospital procurement channels are expanding at 20%+ annually, presenting differentiated pricing and volume dynamics for project planning.

Project-specific demand drivers

• PLI Bulk Drug and Medical Devices
• US generics export opportunity
• Health insurance penetration rising
• Chronic disease burden growth
• Hospital capex expansion in Tier-2/3

The technology selection framework for coated tablet manufacturing is defined by production scale, product complexity, and target market positioning. For facilities within the ₹4.3 crore to ₹20 crore CapEx band, semi-automatic rotary tablet presses (16-35 stations) from Indian manufacturers such as Rimek and Cadmach provide cost-effective compression capability with 80,000-150,000 tablets per hour throughput per press. Fluidised bed processors for granulation and coating from suppliers like Gansons and Niro offer integrated drying, granulation, and coating capabilities within a single vessel, reducing footprint and utility consumption.

Conventional pan coaters or standard perforated coating pans serve conventional film coating requirements for standard generic tablets. Facilities in the ₹20 crore to ₹76 crore CapEx range can consider high-speed rotary presses (27-55 stations) from European manufacturers such as IMA (Italy) or Korsch (Germany) delivering 200,000-500,000 tablets per hour per machine, with fully automated coating systems including Accela-Cota perforated pans or O'Hara coating pans capable of 100-200 kg batch sizes with spray rate precision controls. Blister packaging lines from Uhlmann (Germany) or Bosch (Germany) integrated with vision inspection systems represent the quality-defining capital asset in high-throughput facilities.

Energy benchmarks indicate 180-250 kWh per million tablets for facilities with compression, coating, and primary packaging, with compressed air consumption at 150-200 Nm3 per hour for a medium-scale line. Water consumption for purified water generation averages 3-4 litres per tablet produced, with RO reject water recycling achieving 60-70% recovery rates. Indian pharmaceutical equipment suppliers offer 40-60% lower capital cost versus European equivalents with acceptable reliability for standard generic tablet production, while Chinese equipment suppliers have gained market share in ancillary equipment including tablet de-dusters and metal detectors at 30-40% cost advantage with longer service cycle requirements.

For the Coated Tablet Plant falling within the ₹4.3 crore to ₹76 crore CapEx band, we recommend a debt-equity structure of 70:30 for facilities below ₹15 crore capital cost, leveraging CGTMSE guarantee coverage for SME lending, with equity contribution allocated between promoter capital and PMEGP subsidy for greenfield projects with project cost below ₹2 crore in plant and machinery. Medium and large-scale facilities should target 65:35 debt-equity leveraging priority sector lending classification under RBI guidelines for pharmaceutical manufacturing. Primary lending institutions should include SIDBI for term loan access under its pharmaceutical refinance window, alongside commercial bank relationships with SBI, HDFC Bank, and Axis Bank which maintain dedicated pharmaceutical MSME desks with expedited processing. The PLI Scheme for Bulk Drugs and Medical Devices offers 5-10% production-linked incentives on incremental sales for in-scope Active Pharmaceutical Ingredients, while state-level incentives from Gujarat, Maharashtra, and Telangana include land subsidies, electricity duty exemption, and stamp duty relaxation for pharma park installations. Working capital requirements for pharmaceutical tablet manufacturing typically span 75-90 days in the receivables cycle given hospital and distributor channel payment terms, with raw material inventory averaging 45-60 days covering API, excipients, and packaging materials. Inventory carrying costs of 12-15% annually should be factored into facility-level working capital planning. Letter of credit facilities for API imports from China and Europe require 90-180 day tenures with foreign exchange hedging through forward contracts given rupee volatility against USD and CNY. Project IRR benchmarks of 22-28% are achievable for well-positioned facilities serving chronic therapy segments with stable product portfolios.

The first material risk pertains to regulatory compliance and Schedule M upgrade timelines: facilities failing CDSCO inspection or facing delayed licence grants experience capital cost escalation of 15-25% due to extended construction periods and delayed revenue commencement. The mitigation structure requires engaging regulatory consultants with proven CDSCO filing track records, implementing Schedule M compliance infrastructure from design stage, and maintaining inspection-ready documentation systems through construction. The second risk involves API and excipient price volatility, with imports from China constituting 65-70% of Indian pharmaceutical industry's bulk drug requirements; supply disruptions or duty regime changes could increase production costs by 10-18%.

Mitigation includes diversifying API supply between Chinese and domestic manufacturers, establishing 60-90 day safety stock buffers, and including price escalation clauses in offtake agreements with hospital and institutional buyers. The third risk relates to pricing pressure from NPPA ceiling price revisions for scheduled formulations, which can reduce realisation by 20-40% for products entering price control. Sensitivity analysis scenarios indicate that a 15% reduction in average selling price combined with 10% API cost increase would extend payback period by 1.2-1.8 years, requiring buffer capacity in financial projections to maintain debt service coverage ratios above 1.25x throughout the loan tenure.